Regeneron Announces Review of Biologics License Application for EYLEA; Says Review Extended by 3 Months by FDA

Regeneron Pharmaceuticals, Inc. REGN today announced that it has received notification from the U.S. Food and Drug Administration that the agency has extended its target date to complete the priority review of the EYLEA Biologics License Application for the treatment of neovascular age-related macular degeneration to November 18, 2011, which is a three month extension from the original Prescription Drug User Fee Act action date.